Payment overview · 2025
General Payments
$1,185.57
32 reported records · 13 companies
Healthcare provider profile · identity verified
Subhash Mehta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE MAY COURT HOUSE, NJ · NPI 1255312856
Verified facts
What the public records show
CMS Open Payments records show Subhash Mehta, MD received $1,185.57 in general payments during 2025 across 32 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Lokelma by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nuedexta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $247.53 | 20.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.79 | 18.3% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $123.33 | 10.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $120.07 | 10.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.95 | 9.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $89.76 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.21 | 7.4% | 2 | 2025 |
| Koya Medical, Inc. | Unresolved — no canonical attribution shown | $48.55 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.49 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.33 | 3.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.15 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.37 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.04 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,185.57 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $290.86 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $136.76 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $123.33 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $120.07 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $114.95 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $89.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $87.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.03 | 5 | 2025 |
Source payment records
|
|||||
| DAYSPRING Normalized: dayspring |
Device | Koya Medical, Inc. | $48.55 | 1 | 2025 |
Source payment records
|
|||||
| KOYA MEDICAL Normalized: koya medical |
Device | Koya Medical, Inc. | $48.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.49 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 786 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 676 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 105 |
| Sertraline Hcl | Sertraline Hcl | 443 | 45 |
| Eliquis | Apixaban | 423 | 56 |
| Gabapentin | Gabapentin | 416 | 80 |
| Furosemide | Furosemide | 406 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 375 | 76 |
| Trazodone Hcl | Trazodone Hcl | 332 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 305 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 298 | 81 |
| Mirtazapine | Mirtazapine | 290 | 47 |
| Alprazolam | Alprazolam | 280 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 275 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 63 |
| Metformin Hcl | Metformin Hcl | 259 | 67 |
| Losartan Potassium | Losartan Potassium | 254 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 48 |
| Lisinopril | Lisinopril | 243 | 43 |
| Buspirone Hcl | Buspirone Hcl | 230 | 27 |
| Carvedilol | Carvedilol | 225 | 46 |
| Potassium Chloride | Potassium Chloride | 225 | 33 |
| Tramadol Hcl | Tramadol Hcl | 216 | 66 |
| Omeprazole | Omeprazole | 213 | 47 |
| Famotidine | Famotidine | 206 | 43 |
| Levetiracetam | Levetiracetam | 202 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 201 | 64 |
| Paroxetine Hcl | Paroxetine Hcl | 191 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 184 | 36 |
| Lorazepam | Lorazepam | 182 | 34 |
| Divalproex Sodium | Divalproex Sodium | 178 | 25 |
| Donepezil Hcl | Donepezil Hcl | 157 | 23 |
| Montelukast Sodium | Montelukast Sodium | 157 | 29 |
| Myrbetriq | Mirabegron | 153 | 16 |
| Clonazepam | Clonazepam | 149 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 147 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 131 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 55 |
| Allopurinol | Allopurinol | 129 | 29 |
| Meloxicam | Meloxicam | 126 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 23 |
| Olanzapine | Olanzapine | 120 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 54 |
| Latanoprost | Latanoprost | 107 | 15 |
| Simvastatin | Simvastatin | 107 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 103 | 39 |
| Memantine Hcl | Memantine Hcl | 101 | 15 |
| Risperidone | Risperidone | 95 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | 12 |
| Prednisone | Prednisone | 92 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 89 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 88 | suppressed |
| Entresto | Sacubitril/Valsartan | 87 | 12 |
| Xarelto | Rivaroxaban | 85 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 21 |
| Valsartan | Valsartan | 79 | 16 |
| Azithromycin | Azithromycin | 77 | 71 |
| Ozempic | Semaglutide | 77 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 14 |
| Glimepiride | Glimepiride | 75 | 18 |
| Topiramate | Topiramate | 75 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | suppressed |
| Jardiance | Empagliflozin | 71 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 11 |
| Tradjenta | Linagliptin | 70 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 14 |
| Atenolol | Atenolol | 66 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 62 | suppressed |
| Torsemide | Torsemide | 62 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 59 | 12 |
| Pregabalin | Pregabalin | 59 | 12 |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Baclofen | Baclofen | 57 | 12 |
| Sucralfate | Sucralfate | 57 | 14 |
| Finasteride | Finasteride | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 23 |
| Primidone | Primidone | 52 | suppressed |
| Digoxin | Digoxin | 49 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 14 |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Ibuprofen | Ibuprofen | 47 | 24 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 46 | 23 |
| Hydromorphone Hcl | Hydromorphone Hcl | 46 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Nyamyc | Nystatin | 45 | 22 |
| Aripiprazole | Aripiprazole | 44 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 44 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Loperamide | Loperamide Hcl | 44 | 18 |
| Nystatin | Nystatin | 44 | 22 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 43 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 42 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Diazepam | Diazepam | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 15 |
| Lacosamide | Lacosamide | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 19 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 18 |
| Aptiom | Eslicarbazepine Acetate | 34 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Repaglinide | Repaglinide | 33 | suppressed |
| Nystop | Nystatin | 32 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 22 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 31 | 11 |
| Gemtesa | Vibegron | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Oxycontin | Oxycodone Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Letrozole | Letrozole | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Daptomycin | Daptomycin | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symproic | Naldemedine Tosylate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,185.57 · 32 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AUSTEDO XR, BREZTRI, Cologuard Collection Kit, DAYSPRING, Epclusa, GEMTESA, KOYA MEDICAL, Kerendia, PURIFIED CORTROPHIN GEL, REXULTI, Tymlos, VRAYLAR, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error